Anti-CD20 monoclonal antibody therapy and minimal residual disease status of T-cell/histiocyte-rich large B cell non-Hodgkin lymphoma

2011 ◽  
Vol 57 (2) ◽  
pp. 348-349 ◽  
Author(s):  
Elvis Terci Valera ◽  
Rosane Gomes Queiroz ◽  
María Sol Brassesco ◽  
Carlos Alberto Scrideli ◽  
Fábia Neves ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
B Cell ◽  
Residual Disease ◽  
Antibody Therapy ◽  
Disease Status ◽  
Monoclonal Antibody Therapy ◽  
Non Hodgkin Lymphoma ◽  
Anti Cd20 ◽  
Minimal Residual ◽  
Large B Cell

Antibody Therapy in Aggressive Lymphomas

Hematology ◽  
2007 ◽  
Vol 2007 (1) ◽  
pp. 257-264 ◽  
Author(s):  
Thomas M. Habermann
Keyword(s):  
Monoclonal Antibody ◽  
T Cell ◽  
Natural History ◽  
B Cell ◽  
Antibody Therapy ◽  
Lymphoproliferative Disorders ◽  
Monoclonal Antibody Therapy ◽  
Aggressive Lymphomas ◽  
History Of ◽  
Anti Cd20

AbstractThe aggressive lymphomas are potentially curable. The natural history of certain aggressive lymphomas has been altered by monoclonal antibody therapy. Targeted monoclonal antibody therapy to the CD20 antigen has altered the outcome of patients with diffuse large B-cell lymphoma in patients of all ages. Anti-CD20–based radioimmunoconjugates are being evaluated as radioimmunotherapy approaches in patients who have relapsed and in stem cell transplant settings. Antibody-directed therapy to the B-cell–specific antigen CD22 are ongoing. New approaches include different CD20 antibodies and an antibody to the CD40 antigen, which is a member of the tumor necrosis factor (TNF) receptor family, which is expressed on B-cells. Antibody therapy has been incorporated into CHOP (cyclophosphamide, adriamycin, vincristine, prednisone) therapy and other regimens such as EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) and HyperCVAD (cyclophosphamide, vincristine, adriamycin, dexamethasone). Single-agent anti-CD20 therapy is active in the post-transplantation lymphoproliferative disorders. T-cell antibodies are under evaluation in a number of T-cell lymphoproliferative disorders. Targeted therapy has changed the natural history of a number of aggressive non-Hodgkin lymphomas. This review will describe the contributions of antibody therapies to the treatment of these diseases.

148 90Y-anti-CD20 monoclonal antibody therapy for recurrent B cell lymphoma

1995 ◽  
Vol 32 ◽  
pp. 215 ◽  
Author(s):  
Susan J. Knox ◽  
Michael L. Goris ◽  
Kirk D. Trisler ◽  
Tom A. Davis ◽  
Tina-Marie Liles ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
B Cell ◽  
Cell Lymphoma ◽  
Antibody Therapy ◽  
B Cell Lymphoma ◽  
Monoclonal Antibody Therapy ◽  
Anti Cd20

90Y-ANTI-CD20 MONOCLONAL ANTIBODY THERAPY (IDEC-Y2B8) FOR RECURRENT B CELL LYMPHOMA

1994 ◽  
Vol 16 (2) ◽  
pp. 161 ◽  
Author(s):  
S. J. Knox ◽  
M. Goris ◽  
M. Becker ◽  
S. Fowler ◽  
K. Trisler ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
B Cell ◽  
Cell Lymphoma ◽  
Antibody Therapy ◽  
B Cell Lymphoma ◽  
Monoclonal Antibody Therapy ◽  
Anti Cd20
Sign in / Sign up

Export Citation Format

Share Document